Niraparib Granted FDA Approval for Ovarian Cancer
March 27th 2017The FDA has granted approval for the PARP inhibitor niraparib for maintenance treatment of patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial repsponse to platinum-based chemotherapy.
Asking the Right Questions: Most Women Experience Sexual Side Effects After Breast Cancer
March 27th 2017For patients with breast cancer on aromatase inhibitors, preventive sexual counseling can reduce sexual dysfunction, and it should be provided earlier in treatment, with support from providers.
Setting Standard Criteria for Palliative Care Consults Shows Multiple Benefits
March 27th 2017A recent study found that by using standardized criteria, a more objective assessment of patients and their families’ palliative care needs can be made, which can lead to improvement in multiple quality measures.